Iterum Therapeutics plc (ITRMF) Research & Development (2017 - 2025)

Iterum Therapeutics has reported Research & Development for 9 years, with the latest figure at $1.3 million in Q3 2025.

• On a quarterly basis, Research & Development fell 59.41% year-over-year to $1.3 million in Q3 2025; TTM through Sep 2025 was $4.2 million, a 78.04% decrease from a year earlier, with the FY2024 full-year figure at $10.5 million, down 73.85% from the prior year.
• Research & Development was $1.3 million for Q3 2025 at Iterum Therapeutics, up from $1.0 million in the prior quarter.
• The five-year high for Research & Development was $14.9 million in Q3 2023, with the low at $591000.0 in Q1 2025.
• Average Research & Development over 5 years is $4.3 million, with a median of $3.4 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Research & Development surged 241.19% in 2023, then sank 86.67% in 2024.
• Over 5 years, Research & Development stood at $3.7 million in 2021, then jumped by 57.75% to $5.8 million in 2022, then soared by 66.85% to $9.7 million in 2023, then tumbled by 86.67% to $1.3 million in 2024, then decreased by 2.93% to $1.3 million in 2025.
• The last three Research & Development figures came in at $1.3 million (Q3 2025), $1.0 million (Q2 2025), and $591000.0 (Q1 2025), per Business Quant data.